Collaborative, Licensing and Other Arrangements (Tables)

3 Months Ended

Mar. 31, 2026

The following table summarizes total other revenue recognized for the three months ended March 31, 2026 and 2025:


	Three Months Ended
	March 31,
	2026	2025
Other Revenue	$	$
Amgen royalty revenue	18,297	5,519
Novartis broad markets revenue	5,263	3,522
Other	2,549	(292)
Other Revenue	26,109	8,749

The table below presents the Company’s net product revenue for the three months ended March 31, 2026 and 2025:


	Three Months Ended
	March 31,
	2026	2025
	$	$
Product revenue – gross	1,893,489	1,400,066
Less: rebates and sales returns	(406,160)	(291,536)
Product revenue – net	1,487,329	1,108,530

The following table disaggregates net product revenue by product for the three months ended March 31, 2026 and 2025:


	Three Months Ended
	March 31,
	2026	2025
	$	$
BRUKINSA®	1,094,843	791,664
TEVIMBRA®	206,241	171,164
XGEVA®	89,920	70,423
BLINCYTO®	34,035	23,906
KYPROLIS®	16,971	19,728
POBEVCY®	12,127	13,745
Other	33,192	17,900
Total product revenue – net	1,487,329	1,108,530

Schedule of Collaboration Agreements

Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three months ended March 31, 2026 and 2025 were as follows:


	Three Months Ended
	March 31,
	2026	2025
	$	$
BeOne’s portion of the development funding	58,048	40,519
Less: Amortization of research and development cost share liability	28,645	19,812
Research and development expense	29,403	20,707

		As of
		March 31, 2026
		$
Remaining portion of development funding cap		72,346

As of March 31, 2026 and December 31, 2025, the research and development cost share liability recorded in the Company’s balance sheet was as follows:


	As of
	March 31,	December 31,
	2026	2025
	$	$
Research and development cost share liability, current portion	35,700	64,345

Total research and development cost share liability	35,700	64,345

Schedule of Amounts and Classification of Reimbursement Expense

The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three months ended March 31, 2026 and 2025 as follows:


	Three Months Ended
	March 31,
	2026	2025
	$	$
Cost of sales - product	11,253	7,494
Research and development	(193)	(512)
Selling, general and administrative	(26,442)	(23,948)
Total	(15,382)	(16,966)

Schedule of Payments Due to Collaboration Partners

Upfront and milestone payments incurred under these arrangements for the three months ended March 31, 2026 and 2025 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.


		Three Months Ended
		March 31,
		2026	2025
Payments due to collaboration partners	Classification	$	$
Upfront payments	Research and development expense	544	—


Total		544	—